Soluble CD23 (sCD23) levels correlate with the stage, prognosis and overall survival (OS) of patients with chronic lymphocytic leukemia (CLL). Therefore, we prospectively evaluated sCD23 doubling time (sCD23DT) as a prognostic factor for time to treatment (TTT) and OS in 56 newly diagnosed and untreated CLL patients at Binet stage A, and compared it to the most commonly used biological prognostic factors: lymphocyte doubling time, immunoglobulin variable heavy chain (IgVH) mutational status and f-associated protein-70 (ZAP-70), CD38, and lipoprotein lipase (LPL) expression. In patients with sCD23DT o1 year, the median TTT and OS were 20 and 83 months compared to 141 and 177 months in patients with sCD23DT 41 year (Po0.0001). Among patients with poor prognostic factors (ZAP-70 þ , LPL þ and CD38 þ ), an sCD23DT o1 year identified a subpopulation with a shorter TTT. Patients with unmutated IgVH and an sCD23DT o1 year had a median TTT and OS of 14 and 83 months, respectively, whereas these values were 70 and 4177 months when sCD23DT was 41 year (Po0.0001 and P ¼ 0.0219, respectively). Finally, in a Cox multivariate analysis, sCD23DT was the sole independent prognostic factor for TTT (P ¼ 0.0027). Furthermore, sCD23DT refines the prognosis given by other classical prognostic factors. These observations support the introduction of sCD23 evaluation into the routine assessment of CLL patients.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in North America and Western Europe. In the majority of CLL cases, patients are diagnosed at stage A of the Binet classification and do not require treatment. However, the evolution of this disease is highly variable: some patients will rapidly progress and die, whereas others remain asymptomatic for many years. Recently, major progress has been made in identifying biological prognostic factors for CLL. These factors include the mutational status of the immunoglobulin variable heavy chain region (IgVH), 1, 2 and the expression of CD38, 2, 3 lipoprotein lipase (LPL) 4 and z-associated protein-70 (ZAP-70). [5] [6] [7] [8] Mutational status is currently one of the most powerful prognostic factors used, and patients with unmutated (IgVH-UM) have a shorter time to treatment (TTT) and shorter overall survival (OS) than patients with mutated IgVH. 2, 9 Expression of particular IgVH genes such as IgVH3-21 or IgVH3-72 can also affect the prognosis. 10, 11 However, IgVH gene sequencing is not available for all CLL patients and is not a routine technique in many diagnostic laboratories. 9 More recently, the role of ZAP-70, a tyrosine kinase protein with an important role in T-cell receptor signaling, was investigated in CLL patients. Flow cytometry (FC) studies demonstrated that ZAP-70 intracytoplasmic expression was strongly correlated with disease evolution and was a powerful surrogate of IgVH mutational status. 6, 7, 12 However, a standardized protocol for determining expression has yet to be defined, and there are some patients with discordance between IgVH mutational status and ZAP-70 expression. 6, 7, 12 CD23, a 45-kDa transmembrane glycoprotein, is a lowaffinity receptor for the immunoglobulin E (IgE) expressed on lymphoblastoid B cells. The CD23 protein is unstable, and its soluble form is found in serum. 13 We previously reported that CLL patients had a soluble CD23 (sCD23) level that was 3-500 times higher than patients with other lymphoproliferative diseases and than healthy subjects; we also observed that sCD23 was a marker of tumor burden. 14 Other studies have reported that the sCD23 level is associated with shorter progression-free survival [15] [16] [17] and with CD38 and ZAP-70 protein expression. 18 We also found that the sCD23 level is a prognostic factor for survival among untreated patients with Binet stage A CLL, and that doubling the sCD23 level increased the risk of developing more aggressive disease. 19 A simple and reproducible test is still needed to identify in newly diagnosed stage A CLL patients, those patients with a higher risk of progressive disease. Toward this end, we prospectively evaluated the impact of sCD23 doubling time (sCD23DT) in the first year of follow-up of newly diagnosed stage A-untreated CLL patients in terms of TTT and OS. We also compared sCD23DT to well-established biological prognostic factors: IgVH mutational status, lymphocyte doubling time (LDT), ZAP-70, LPL and CD38 expression.
Patients, materials and methods

Patients, sample collection and RNA extraction
This prospective study was approved by our Institutional Review Board and was based on peripheral blood samples obtained with informed consent from newly diagnosed and untreated Binet stage A CLL patients. From January 1991 to June 2007, 56 untreated stage A CLL patients were evaluable for this study. Most of the patients were treated with alkylant agent as first-line treatment and fludarabine-based regimen as second-line therapy. After 2000, more aggressive therapies (FC, RFC, y) were introduced. The number of patients included in the study before and after 2000 was not statistically different in the two groups (sCD23DT greater or lower than 1 year). Patients who required treatment at the diagnosis were excluded. The 27 males and 29 females had a typical CD19 þ CD5 þ CD23 þ phenotype and blood leukocyte counts between 1 Â 10 10 and 25 Â 10 10 cells per l. The median age at diagnosis was 63 years (range, 43-89 years) and the median survival after diagnosis was 177 months (range 3-177 months). The median follow-up duration was 64 months (range, 6-177 months). Therapy was started according to the standard National Cancer Institute (NCI) criteria. 20 Table 1 summarizes patient features. For some patients, ZAP-70, LPL, CD38 expression or the IgVH status was unavailable because of lack of biological material. Moreover, it was not always possible to isolate monoclonal sequences for routine IgVH analyses. TTT and OS were calculated from the time that the first sample was collected. All treatment and death events included in this study were CLL related. Peripheral blood mononuclear cells were isolated by density-gradient centrifugation over Linfosep (Biomedics, Madrid, Spain). B cells were purified with a CD19 þ magnetic-bead system (MidiMACS, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Mean B-cell purity as measured by FC was 499%. Total RNA was extracted from purified CD19 þ cells in a single step with TriPure Isolation Reagent (Roche Applied Science, Vilvoorde, Belgium). 21 Soluble CD23 and lymphocyte doubling time determination sCD23 serum levels were determined using an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (sCD-23 EASIA; Biosource International, Camarillo, CA, USA). Standards were used to fully quantify sCD23 level and provided controls were loaded in each experiment to monitor the assay performance and the interassay variability. When these controls were out of range, the experiment was excluded. During the first year after diagnosis, sCD23 was dosed each 3 or 6 months according to patient follow-up visit. A minimum of two sCD23 dosage (a minimum of 6 months apart) were used to determine sCD23DT. All different patient time points were analyzed in the same assay to allow more reliable comparison. sCD23DT was defined as the time taken for serum sCD23 concentration to reach a double value of that corresponding to the initial observation without any treatment. The calculation of sCD23DT was performed with the same method than for LDT. 22 The sCD23DT cutoff was fixed to 1 year as it was previously the case for the LDT. 22 LDT was assessed according to Montserrat et al.
22
FC measurement of ZAP-70 and CD38 expression
We measured cytoplasmic ZAP-70 protein and surface CD38 protein expression by FC as previously described. 23 ZAP-70 and CD38 expressions were defined as positive if 20% (ZAP-70) or 7% (CD38) of the cells were positive in a standard three-color FC analysis. 6, 24 The 20% cutoff for ZAP-70 is commonly accepted in the literature although the 7% cutoff for CD38 was determined using receiver operating characteristic (ROC) curve analysis maximizing the concordance between the mutational status and the ZAP-70 status. 23 
qPCR analysis of LPL expression
We used 25 ng cDNA (produced by standard reverse transcription) in a qPCR reaction with SYBR Green PCR Master Mix (Applied Biosystems, Rotterdam, the Netherlands) and 0.32 mM of gene-specific forward and reverse primers (Invitrogen Life Technologies, Merelbeek, Belgium). Primers sequences used for LPL have been published previously. 25 Results were standardized using peptidylprolyl isomerase A (cyclophilin A) gene expression. 23, 26 Standard real-time PCR was performed on an ABI Prism 7900 HT (Applied Biosystems). A calibrator sample (cDNA from the Namalwa cell line, a human B-lymphoid leukemia cell line from ATCC) was included as a control in each experiment. In all cases, dissociation curves were used to confirm PCR specificity. We analyzed the data with the comparative threshold cycle (DDC t ) method.
IgVH gene mutational analysis
We conducted IgVH gene mutational analysis as previously described 27 and aligned sequences with those in the international ImMunoGeneTics information system database (http:// imgt.cines.fr). Sequences with p2% deviation from any germ line IgVH sequence were considered unmutated. 9 
Statistical analysis
We used w 2 Pearson's statistics (with the Yates continuity correction for 2 Â 2 tables) to describe associations between clinical markers, and used Cramer's V statistic to quantify the strength of association between two variables (that is information unobtainable from the P-value). Values of 0.20-0.35 indicate a moderate relation, 0.36-0.49 indicate a substantial relation and values X0.50 a strong relation. We plotted OS and TTT distributions with the Kaplan-Meier method and used the log-rank test with GraphPad Prism 5.0 to compare the distributions. Univariate and multivariate Cox regression analyses were used to evaluate the effects of the different prognostic factors on TTT and/or OS. We included sCD23DT (X1 vs o1 year), CD38 expression (X7 vs o7%), FC-measured ZAP-70 expression (X20 vs o20%), LPL mRNA expression (using a cutoff of 6-fold of LPL mRNA expression in the Namalwa line), and LDT (X1 vs o1 year) as potential prognostic factors in our analysis. All variable included in the Cox regression were first binarized regarding the described cutoffs. All tests were two sided. A P-value o0.05 was considered statistically significant. All analyses were performed with SPSS 13.0 software.
Results
Prognostic significance of sCD23DT and correlation with classical prognostic factors
Among the 56 patients, 15 had an sCD23DT of o1 year during the first year of follow-up, and 41 had an sCD23DT 41 year. Univariate Cox regression analysis also showed that the sCD23DT was a significant predictor of TTT and OS (Table 2) . Median TTT and OS were only 19.5 and 82.6 vs 141.2 and 176.5 months in patients with an sCD23DT of o1 year vs an sCD23DT of 41 year, respectively (Po0.0001; Figure 1 ). sCD23DT was also significantly associated with IgVH mutational status (P ¼ 0.0031), ZAP-70 expression (P ¼ 0.0019), LPL expression (Po0.0001) and LDT (Po0.0001). We did not find an association between sCD23DT and CD38 expression (P ¼ 0.2754; Table 1 ).
Prognostic significance of IgVH mutational status
IgVH mutational status is recognized as one of the most powerful biological factor in terms of predicting CLL course. We thus analyzed the impact of this factor on TTT and OS as sCD23DT is a powerful prognostic factor in CLL N Meuleman et al Table 1 Cross-tabulation of prognostic markers vs IgVH mutation status and sCD23DT 
Prognostic significance of other biological prognostic factors
The effect of IgVH mutational status, LDT, and ZAP-70, LPL, and CD38 expression on the median TTT and OS was analyzed by the Kaplan-Meier method. All factors were found to be significant TTT predictors, but only IgVH mutational status, ZAP-70, and LPL were significant OS predictors. The results are summarized in Figure 1 and Table 3 . However, using a univariate Cox regression model, only sCD23DT was found to significantly predict OS (Table 2) .
Additional impact of sCD23DT on other prognostic factors
We also used the Kaplan-Meier method to analyze whether using sCD23DT would provide additional prognostic information in terms of TTT and OS. Interestingly, we observed that in patient group with or without poor prognostic factors, sCD23DT allowed to make a new separation in two subgroups of different prognosis.
An sCD23DT o1 year identified a group of patients with a significantly shorter median TTT within the IgVH-UM group (Po0.0001). In IgVH-mutated patients, the sCD23DT did not provide additional information; however, there were only two mutated patients with sCD23DT o1 year (P ¼ 0.054). We also observed that sCD23DT o1 year can define a shorter TTT in the group of ZAP-70 À and ZAP-70 þ patients (Po0.0008 and Po0.0001, respectively). As shown in Figure 2 and Table 3 ). Most interestingly, when we introduced all the variables (sCD23DT, IgVH mutational status, LDT, and ZAP-70, CD38, and LPL expression) in a multivariate Cox regression analysis (N ¼ 42), the sole independent predictor for TTT was the sCD23DT (P ¼ 0.0027; Table 2 ). Analysis of OS prediction by multivariate analysis was not informative due to the limited number of event (N ¼ 5).
Discussion
CLL is a disease with extremely variable clinical presentation. Currently, a routine blood test is used to diagnose the majority of CLL patients with asymptomatic stage A disease with unpredictable progression. 2 In 1988, our group reported that IgEbinding factor (sCD23) was a marker of CLL that correlated with tumor load.
14 In 1996, we reported that patients with a sCD23 level above the median value had a worse prognosis and reduced OS compared to those with a sCD23 level below the median value (53 vs 100 months). These results were confirmed in the present study (data not shown). An sCD23 level longitudinal analysis revealed that the sCD23DT clearly correlated with an increased risk of progression. 19 In this prospective trial, we studied the impact of sCD23DT on TTT and OS in newly diagnosed and untreated stage A CLL patients. We found that sCD23DT is a powerful prognostic factor for both TTT and OS. Very interestingly, we observed that sCD23DT is more powerful that sCD23 itself as prognostic factor for TTT and OS (data not shown). We also assessed the impact of other recently identified biological prognostic factors on TTT and OS. ZAP-70 expression has been reported to be a surrogate for IgVH mutational analysis 6 and is one of the most 
TTT OS
sCD23DT is a powerful prognostic factor in CLL N Meuleman et al Table 3 Supplementary prognostic power of sCD23DT on TTT Table 3 .
sCD23DT is a powerful prognostic factor in CLL N Meuleman et al Table 3 .
sCD23DT is a powerful prognostic factor in CLL N Meuleman et al powerful prognostic factors. 7, 12 Nevertheless, there is still some debate about the best method to evaluate ZAP-70 expression and about the reproducibility of results in different labs; 28 further, there is a small proportion of patients who show discordance between their biological prognostic status (low-or high-risk) and their clinical progression. 7 We thus analyzed the impact of these biological factors (ZAP-70, LPL, CD38, and IgVH mutational status) on TTT and OS in our study population. Concomitantly, we evaluated whether sCD23DT provided additional prognostic information.
In agreement with other studies, we confirmed that IgVH mutational status and ZAP-70 expression are strong predictors of disease evolution and OS. In the current study, LPL correlated with TTT and OS. LPL expression has been reported to be a strong prognostic factor for TTT, and some studies found that LPL correlated with OS. 29, 30 However, we previously reported that LPL did not correlate with OS. 23 This difference may be due to the characteristics of the different study populations. Indeed, in this prospective study, only stage A patients were included in the analysis.
CD38 positivity was significantly associated with TTT but had no impact on OS. CD38 expression has been reported to be an indicator of disease progression and survival. 2, 31 It was suggested that this marker may be used as a surrogate for IgVH, but subsequent studies demonstrated discordance between CD38 expression and IgVH status. 32 In addition, there is still discussion about the threshold for CD38 expression, and it has also been clearly demonstrated that CD38 expression is not stable during disease evolution. 32, 33 CD38 expression remains a disease progression indicator, but it is not as strong as ZAP-70 expression or IgVH mutational status.
Interestingly, we observed that in the population with a poor prognosis (ZAP-70 þ or LPL þ , or IgVH-UM), sCD23DT allowed us to isolate two different populations: one population (sCD23DT o1 year) with a short median TTT (o14 months, all groups mixed up) and OS (o83 months); and another population (sCD23DT 41 year) with a longer TTT (462 months, all groups mixed up) and OS (4177 months).
For low-risk patients (that is ZAP-70-and CD38-negative), sCD23DT also allowed us to isolate two populations with different prognosis, but not in the IgVH-mutated or LPL-negative population. This is probably due to the low number of UM or LPL-negative patients who had an sCD23DT o1 year and reflects the strong correlation between UM status, absence of LPL expression and stable sCD23 level.
These analyses reveal that sCD23DT is a powerful prognostic factor that allows the identification of patients with a worse prognosis or a less indolent evolution defined by the other recently admitted prognostic factors. We hypothesize that sCD23 is more highly expressed in aggressive CLL cells but is also correlated with the total tumor load; thus, sCD23DT provides a dynamic picture of the disease.
Several cytogenetic abnormalities have also been proposed as prognostic factors. 34, 35 However, the correlation between these chromosomal aberrations and the sCD23DT could not be evaluated in our cohort due to a lack of karyotypic abnormalities in most of patients. Tobbin et al. 36 and Ghia et al. 10 reported that CLL patients carrying Ig mutations such as IgVH3-21 have a particularly poor outcome, meaning that the prognostic value of the IgVH gene is more complex that just 'mutated' or 'unmutated'. In our study, sCD23DT was significantly correlated with mutational status and with ZAP-70 and LPL expression, but among IgVH-mutated CLL patients, sCD23DT was able to identify a subpopulation with a poor prognosis.
It has also been reported that sCD23 is correlated with the LDT. 18, 37 In order to evaluate whether sCD23DT is linked to LDT, we analyzed the impact of this prognostic factor in our population. LDT was significantly correlated with TTT, but not with OS, whereas sCD23DT was strongly correlated with OS. We observed that sCD23DT provides additional value for analyzing patients with a LDT 41 year. For patients with a good prognosis according to LDT (41 year), sCD23DT identified a group of patients with a more aggressive form of the disease. Patients with a LDT 41 year but an sCD23DT o1 year had a significantly reduced TTT (21 months) and OS (81 months) compared to a very long median TTT (141 months) and OS (177 months) for patients with LDT and sCD23DT 41 year. This confirms that sCD23DT level gives more information than LDT and is a dynamic marker of the total tumor load.
CD49d/a4-integrin expression has also been recently reported as a simple, powerful marker for untreated CLL. 38 This marker is strongly correlated with CD38 expression, but does not appear to be a better indicator than the mutational status. Our study did not look at CD49d/a4-integrin expression, and Gattei et al. did not analyze sCD23DT. Further investigation will be needed to compare these two markers.
Finally, we evaluated many biological prognostic factors for CLL using a multivariate Cox regression model: this analysis revealed that sCD23DT was the sole independent prognostic factor for TTT. All our observations suggest that sCD23DT is currently the most powerful biological indicator for determining the prognosis of stage A CLL patients in terms of TTT and OS. In addition to being a powerful prognostic factor, sCD23DT is easily determined using a simple ELISA test that is simple, reproducible and relatively inexpensive.
Conclusions
In conclusion, sCD23DT is an independent and dynamic powerful prognostic factor for TTT and OS in untreated stage A CLL patients. sCD23DT correlates with IgVH mutational status and LDT, as well as with ZAP-70 and LPL expression, and refines the prognosis determined by IgVH mutational status, LDT, and ZAP-70, CD38, and LPL expression. Our observations indicate that sCD23 determination should be used for routine monitoring of CLL patients to better identify high-risk CLL patients who might benefit from earlier treatment.
